Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
ResearchHealthcare, Consumer Staples, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Nucleic Acid Drug CDMO Olipharma Raises Tens of Mns of CNY in Pre-Series A Round
As a new way to treat diseases, gene therapy has higher R&D investment and risk than biochemical drugs. Both pharmaceutical giants and start-ups tend to collaborate with outsourcing service providers, which brings business opportunities to cell and gene therapy contract development and manufacturing organizations (CDMOs).
Yesterday 09:59 PM
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM